Abstracts tagged "patient outcomes"

Abstract Number: 2721 • 2014 ACR/ARHP Annual Meeting
Patients’ Perspective of Skin Involvement in Systemic Sclerosis
Ada Man¹, Amy Wu¹, Jessica Ziemek², Romy Christmann¹, Robert W. Simms¹, David T. Felson³ and Robert Lafyatis⁴, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Arthritis Center, Boston University, Boston, MA
Background/Purpose: Skin tightness and other abnormalities of the skin are the hallmark features of systemic sclerosis (SSc). While skin involvement may significantly impact a…
Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting
Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity
Francesca Ometto¹, Costantino Botsios², Livio Bernardi¹, Bernd Raffeiner^2,3, Leonardo Punzi⁴ and Andrea Doria⁴, ¹Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, ⁴Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Jos Hendrikx¹, Jaap Fransen², Alessandro Toniolo³ and Piet L.C.M. van Riel⁴, ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pfizer Pharmaceuticals, Rome, Italy, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…
Abstract Number: 2459 • 2013 ACR/ARHP Annual Meeting
Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis
Désirée M. van Der Heijde¹, Philip J. Mease², Aileen L. Pangan³, Sumati A Rao³, Naijun Chen³ and Mary Cifaldi³, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) was approved in the European Union for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation…
Abstract Number: 2449 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Outcome In Male Versus Female Patients Of The Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort
Suzanne Arends^1,2, Fiona Maas¹, Eveline van der Veer³, Reinhard Bos², Monique Efde², Martha K. Leijsma¹, Hendrika Bootsma¹, Elisabeth Brouwer¹ and Anneke Spoorenberg¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Ankylosing Spondylitis (AS) occurs more often in males than in females. Most women tend to have milder disease and may therefore be underdiagnosed. Male…
Abstract Number: 2284 • 2013 ACR/ARHP Annual Meeting
How Well Do Generic Patient Reported Outcomes Measurement Information System Instruments Capture Health Status In Rheumatoid Arthritis?
Susan J. Bartlett^1,2, Ana-Maria Orbai³, Trisha Duncan³ and Clifton O. Bingham III³, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: PROMIS offers precise, reliable generic measurement of physical, mental and social health across chronic conditions. However, little is known about the validity and performance…
Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Frank Buttgereit¹, Jeffery Kent², Robert Holt², Amy Grahn³, Patricia Rice⁴, Rieke Alten⁵ and Yusuf Yazici⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶New York University, New York, NY
Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be…
Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting
Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Rieke Alten¹, Robert Holt², Amy Grahn³, Patricia Rice⁴, Jeffery Kent², Frank Buttgereit⁵ and Allan Gibofsky⁶, ¹Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Medicine and Public Health, Hospital for Special Surgery, New York, NY
Background/Purpose: A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
Abstract Number: 1934 • 2013 ACR/ARHP Annual Meeting
Scores On The Multidimensional Health Assessment Questionnaire (MDHAQ) For “Walk 2 Miles Or 3 Kilometers,” “Poor Sleep,” and “Participate In Recreation,” Are Higher, Indicating Poorer Status, Than Scores For 8 Activities Derived From The Health Assessment Questionnaire (HAQ)
Kathryn Gibson¹, Sung-Hoon Park^2,3 and Theodore Pincus⁴, ¹Liverpool Hospital and University of New South Wales, Sydney, Australia, ²NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: The HAQ [Arthritis Rheum 1980;23:137] has been used in almost all rheumatoid arthritis (RA) clinical trials conducted over the last two decades, and provides…
Abstract Number: 1733 • 2013 ACR/ARHP Annual Meeting
Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Gerd Burmester¹, Tsutomu Takeuchi², Olga Barbarash³, Duncan Porter⁴, Didier Saurigny⁵, David Close⁵, Alex Godwood⁵, Yoojung Yang⁶ and Ancilla W. Fernandes⁶, ¹Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, ⁴Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, ⁵MedImmune, Ltd, Cambridge, United Kingdom, ⁶MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with significant pain and loss of physical function. We evaluated self-reported pain and physical function in adults patients with…
Abstract Number: 1546 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Maxime Dougados¹, Wen-Chan Tsai², Diego Luis Saaibi³, Randi Bonin⁴, Jack Bukowski⁵, Ronald Pedersen⁶, Bonnie Vlahos⁷ and Sameer Kotak⁸, ¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ²Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan, ³MEDICITY S.A.S, Bucaramanga, Santander 681001, Colombia, ⁴Pfizer Inc, Collegeville, PA, ⁵Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁸Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). This analysis compares the impact of etanercept (ETN) vs…
Abstract Number: 1557 • 2013 ACR/ARHP Annual Meeting
Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction
M. Elaine Husni¹, Daniel Duch² and Neil J. Korman³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Curatio CME Institute, Exton, PA, ³Case Western Reserve Univ (Uni, University Hospitals Dermatolo, Cleveland, OH
Background/Purpose: Despite the availability of more targeted therapies for psoriatic arthritis (PsA), an assessment of the impact these have had on patient well-being has not recently…
Abstract Number: 1049 • 2013 ACR/ARHP Annual Meeting
Formal Education Level Explains Variation In Rheumatoid Arthritis (RA) Core Data Set Measures and Indices In Korean Patients At Higher Levels Of Significance Than Age, Sex, and Duration Of Disease
Sung-Hoon Park^1,2, Isabel Castrejón³, Jung-Yoon Choe¹, Seong-Kyu Kim¹, Hwajeong Lee¹, Sang Gyu Kwak¹ and Theodore Pincus³, ¹Catholic University of Daegu School of Medicine, Daegu, South Korea, ²NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Poor health is associated with low socioeconomic status (SES), with higher prevalence, greater severity and earlier mortality of many diseases, including rheumatoid arthritis (RA).…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].